Sarah Glass | Chief Operating Officer
n-Lorem Foundation
Sarah Glass, PhD, is Chief Operating Officer at the n-Lorem Foundation, where she leads global operations to bring individualized RNA-based medicines to patients with nano-rare diseases—those affecting only a single individual worldwide. Trained as a geneticist and driven by her personal experience as a parent of a child with a nano-rare condition, Dr. Glass has spent her career bridging science, compassion, and operational excellence. Prior to n-Lorem, she led rare disease and genomic medicine programs at Parexel, Teva Pharmaceuticals, and GlaxoSmithKline. Her work focuses on building sustainable, scalable solutions that deliver life-changing therapies to those who previously had no options.
Appearances:
Day 1 - World Orphan Drug Congress USA 2026 @ 11:30
Where is N-of-1 Going?
N-of-1 is evolving rapidly through rapid developments in the science, therapeutic delivery mechanisms and the regulatory landscape. An informal discussion with leaders in the field of N-of-1 on where the future lies with this approach to treating nano-rare diseases. This fireside chat will address:
- What therapeutic modalities are currently being used in N-of-1 treatments, and what have we learned from the last 5-7 years
- If the regulatory landscape continues to expand and evolve, what new types of personalized therapies could realistically become N-of-1 candidates in the next few years
- How does N-of-1 drug development compare with traditional therapeutic development—scientifically, operationally, and in terms of patient impact? What learnings from N of 1s have been applied to broader rare disease populations
- What will it take for the individualized treatment field to continue to grow
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events